| CAR-T细胞免疫治疗实体瘤的研究进展 |
| |
| 引用本文： | 姚铮,李子涵,高利明,胡星,陈颜,潘文琦,李谦.CAR-T细胞免疫治疗实体瘤的研究进展[J].中国药科大学学报,2021,52(4):496-504. |
| |
| 作者姓名： | 姚铮 李子涵 高利明 胡星 陈颜 潘文琦 李谦 |
| |
| 作者单位： | 中国药科大学生命科学与技术学院，南京 210009,中国药科大学生命科学与技术学院，南京 210009,中国药科大学生命科学与技术学院，南京 210009,中国药科大学生命科学与技术学院，南京 210009,中国药科大学生命科学与技术学院，南京 210009,中国药科大学生命科学与技术学院，南京 210009,中国药科大学生命科学与技术学院，南京 210009 |
| |
| 摘 要： | 近年来过继性细胞免疫疗法因效果显著而得到广泛认可，尤其是CD19特异嵌合抗原受体（CAR）的自体T细胞治疗恶性血液瘤取得成功。本文总结实体肿瘤存在肿瘤免疫微环境、靶点不均一以及免疫抑制性受体等原因导致CAR-T无法有效治疗，提出改进CAR-T细胞以提高T细胞浸润、共表达细胞因子与酶以及修饰相关受体等方式提高CAR-T抗实体肿瘤活性，为后续CAR-T细胞治疗实体肿瘤研究奠定理论基础。
|
| 关 键 词： | 嵌合抗原受体T细胞 实体瘤 免疫微环境 免疫治疗 进展 |
| 收稿时间： | 2020/9/23 0:00:00 |
| 修稿时间： | 2021/6/25 0:00:00 |
Advances of research on CAR-T cell immunotherapy for solid tumors |
| |
| YAO Zheng,LI Zihan,GAO Liming,HU Xing,CHEN Yan,PAN Wenqi and LI Qian.Advances of research on CAR-T cell immunotherapy for solid tumors[J].Journal of China Pharmaceutical University,2021,52(4):496-504. |
| |
| Authors: | YAO Zheng LI Zihan GAO Liming HU Xing CHEN Yan PAN Wenqi and LI Qian |
| |
| Institution: | School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China,School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China,School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China,School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China,School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China,School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China,School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China |
| |
| Abstract: | Adoptive cellular immunotherapy has been widely recognized in recent years due to its remarkable results, especially the success of CD19-specific chimeric antigen receptor (CAR) autologous T cell therapy for malignant hematoma. Previous studies have found the existence of tumor immune microenvironment, heterogeneous targets, and immunosuppressive receptors in solid tumors, which has led to the shortcomings of CAR-T treatment of solid tumors. This article proposes the methods to improve CAR-T cells to increase T cell infiltration, co-expression of cytokines and enzymes and modification of related receptors in order to enhance the anti-solid tumor activity of CAR-T, laying a theoretical foundation for the follow-up CAR-T cell treatment of solid tumors. |
| |
| Keywords: | chimeric antigen receptor T cell solid tumor immune microenvironment immunotherapy advances |
|
| 点击此处可从《中国药科大学学报》浏览原始摘要信息 |
| 点击此处可从《中国药科大学学报》下载免费的PDF全文 |
|
